been Susan. for and Good XXXX challenges. everyone, today's call. both and a morning, focused you, opportunities thank year joining Thank you on amidst execution has
to we All updated continue the we guidance reflect be an of and view improving our trends intact. remains sales financial to EXPAREL year. the adjusting While year remainder are opportunities, guidance by today, other of encouraged near-term full
data established based conditions. and We projected guidance market current alongside historical on
year $XXX to EXPAREL forecasting $XXX million be to now are We million. full sales
remain full and growing guidance substantial ] Costera we -- While the the impacts We to within and our front we've portfolio, we significant in in for confidence maintained prospects the conviction and potential adjust are strong are unlock disappointed groundwork in the to us. commercial its EXPAREL of in year strong the no way untapped value. we laying [ have
us business environments. in patient-focused built enabling an We while effectively maintaining attractive all financial manage have to discipline,
discipline significantly of and ongoing revenues adjusted of resulted gross margins EBITDA quarter $XXX improving million. $XX Third in positive million, operating
that to improving also positioned we flows one, focused in exclusivity sites and With return. revenues care. advancing deploying return medium-term by significant across meaningful remain manner fueled three, short- X and to and to believe gross XXXX, are durable pain priorities: a well cash opportunities; through on access growing maximize all margins; we will by EXPAREL shareholder capital We growth non-opioid and management two reimbursement of expanding through
gross start continue consolidated to margins improving with quarter third important where XX%. make progress with to I'll we margins,
facility EXPAREL, targets exceed our EXPAREL For San quarter to achieved of third output Diego XX%. continues and margins
XX% our addition, In expect ] margins at United improvements to exit upon gross quality positively earlier we facility maintain in to shape going high with margins. year [ remain are Kingdom the and implemented margins Top line, this XXXX significant range, we or impacting we improve now good the in Swindon forward. these
to regulatory gross approval serve decommission San On of our to X submitted improve in This also recently manufacturing XXXX positions facility us approval application will San XX-liter us early margins and for a Diego. higher-cost FDA will the the as it in supplemental Diego. an XXX-liter our facilities front, for EXPAREL allow we further to
now procedure saw to of with by commercial average on daily the we starting more where EXPAREL, grew X%. side business, third volume Turning the specifics quarter
providing of the as non-opioid not a patients Our mission possible. to aim as has changed with many alternative
shareholders ahead Anesthesiology of and We EXPAREL. or education a milestones. of ASA, the reinforce about continue to our new American key partnership educate we the awareness with Society Recently, EXPAREL to announced benefits of
are is nerve new additional month last indications. patient with optimizing the and Our improving the with meaningful in and patient anticipated up our block with XX, a aligned PDUFA ally focus productive of meeting ASA's coming our lower launch on annual several a action are development We around presence on had building programs mission date at lower extremity momentum of are November nerve anesthesiologists who extremity a key block outcomes. and care
our key of reach lower expanding and annual $XXX more To expected million label years the you, million lower foot X accounts significantly sales our and knee, these X in launch represent and which extend rolling within ankle, than meeting to our launch. nerve with collectively of annual surgeries will education with remind extremity leg and with within a procedures out we Immediately X broad promotion at key exceed will January. national blocks following begin approval,
X.XX be pain, overwhelmingly significance opioid-free days launching patients. and consumption We of to will achieving and opioid statistical versus supporting less percentage positive with single-dose body demonstrate and the data values of of as X superiority product only bupivacaine, first for an than postsurgical EXPAREL of p safely
[ of outcomes knee, blocks, care. anesthesia were lower across positive and value nerve and sites surgeries adduction and attractive all a proposition very These with sonic achieved to foot ml leg EXPAREL a ] speaking the for dose XX lower ankle community
to market Turning access.
benefit low-margin reimbursement are soft procedures. especially XX% EXPAREL EXPAREL's to of believe relevant access in milligram place greatly pain. programs offer where settings. of the expand ahead reimbursing product-specific procedures programs setting, EXPAREL user no to to sufficient current for inpatient particularly regimens, tissue invest hospital unique our settings to pain we control, at $X.XX patient in We of these significantly the per CXXXX sparing code non-opioid our base surgery currently With help impede from is hospital lack continue market continuing non-opioid outside taking will outpatient of in the We customers ambulatory which
non-opioid soft fully reimbursed or ASP, CMS as settings. reimbursing of the million and providing CMS care now pathway no solution a will all XX reimbursement is EXPAREL-relevant pain it procedures. by performing providing adopted recently price, cost military that is mandate a X%. CXXXX across for ahead methodology with via see reimbursement pain also at opportunity average sites settings, million barrier and XX We growth a the outpatient EXPAREL reimbursement significant and in government covers management nearly of selling eliminate outpatient plus will Medicare which lives, lower-margin TRICARE, tissue ambulatory procedures pain No
into We expect adopt grow policies opportunity a multi-$XXX commercial no payers pain will over million reimbursement Medicare time. as
patients cost to existing vulnerable while By offering and new favorable growing of the opioid our base net and alleviate roughly are by low-income to entities challenges helping a a gross industry are reduced to communities most XX%. eligible to addiction. XXXB, is program business we for investing volumes an highly pricing XXXB user with price Our in maintaining EXPAREL where and
are and also purchasing is GPOs, or solidify the and no our pain, [indiscernible] grow to of cost to proposition -- organizations, group and working right our EXPAREL. partnering it business select block time the We begin with on value
network are and launching XXXX, partnerships, pricing. will hospitals be a of Through care in offering systems health broad preferred these EXPAREL which we we
ongoing will price access significantly non-opioid have believe customers of We a making true while over to volumes expand pressures, We will a expect our while mid-single-digit by on financial staying this we management growing broadly patient accessible. our our time. hospital selling navigate overall net impact pain mission helping
also and expose practice health for to disincentivized postsurgical will partners drill opioids cost-driven Our patients call short-acting They generic best pain and serious risks. GPO capital that combination, management approaches. regimens compounded reinforce directives illicit
The to proliferation a is of outside patients compounders health our and threat care system.
As pivotal or insert and They regulatory we Nordisk activity. data. marketing support ]. legal Lilly employ with from safety [ FDA the a saw do benefit misleading compounders These activities recent or practices promotional to product approval GLP-X pharmacy have and package of any efficacy not the Novo without
injunctive These in with multipronged a similar activity. ] of advancing include taken relief We as the enforcement directly the actions products. and marketing working Act, law and GLP-X recent Lanham strategy under to serious to illegal lawsuits legal authorities well are regulatory [ address the support seeking as the
surgeon conversion X the the million. XXXX. to $XX United the opioid-sparing benefit pain EXPAREL of quantify paving more larger XX in of offer we To activities, products approximately by States control. an like a our by accessing upside than to patients of shows for these research potential be to XX% Act A these with in the and these providers want will partnerships, who no that EXPAREL These of million are programs would the superior implementation mL user programs building ahead base XXXB dose a pool GPL extensive XXXX. Through sold way us in sales anesthesia our pain leverage significantly and are
track market procedures of year-over-year sports of for rig pharmacy several expanding burden low-back and the foot long-acting nerve to office a iovera pain milestones in iovera orthopedic to their drug-free on initiating products pay cash initiatives, and launching new customers generating reduce for risk and new on and and ZILRETTA smart medicine, shoulder quarter coming for Switching our fracture registration for and osteoarthritic the ankle, iovera knee practices. through thoracotomy study for gears benefit of studies. pediatrics, study strong to a to Expanding the with tips ZILRETTA spasticity developing label posted administrative retic pain year. the data block in targeted management direct-to-consumer include investigator-initiated while expansion shoulder the iovera treatment iovera, patients use growth and a specialty both These for third oscuorarthritis, pain
throughout are confident executing XXXX, focused best-in-class of we we and be will to grow these balance the the portfolio. For continue keenly will the that value-creating commercial year strategies on
With over turn Charlie for his financial the Charlie? that, report. to I'll call
